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Abstract
Background: Duchenne muscular dystrophy (DMD) is an X-linked myopathy resulting from the production of a
nonfunctional dystrophin protein. MicroRNA (miRNA) are small 21- to 24-nucleotide RNA that can regulate both
individual genes and entire cell signaling pathways. Previously, we identified several mRNA, both muscle-enriched
and inflammation-induced, that are dysregulated in the skeletal muscles of DMD patients. One particularly muscle-
enriched miRNA, miR-486, is significantly downregulated in dystrophin-deficient mouse and human skeletal
muscles. miR-486 is embedded within the ANKYRIN1(ANK1) gene locus, which is transcribed as either a long
(erythroid-enriched) or a short (heart muscle- and skeletal muscle-enriched) isoform, depending on the cell and
tissue types.
Results: Inhibition of miR-486 in normal muscle myoblasts results in inhibited migration and failure to repair a
wound in primary myoblast cell cultures. Conversely, overexpression of miR-486 in primary myoblast cell cultures
results in increased proliferation with no changes in cellular apoptosis. Using bioinformatics and miRNA reporter
assays, we have identified platelet-derived growth factor receptor b, along with several other downstream targets
of the phosphatase and tensin homolog deleted on chromosome 10/AKT (PTEN/AKT) pathway, as being
modulated by miR-486. The generation of muscle-specific transgenic mice that overexpress miR-486 revealed that
miR-486 alters the cell cycle kinetics of regenerated myofibers in vivo, as these mice had impaired muscle
regeneration.
Conclusions: These studies demonstrate a link for miR-486 as a regulator of the PTEN/AKT pathway in dystrophin-
deficient muscle and an important factor in the regulation of DMD muscle pathology.
Background
Duchenne muscular dystrophy( D M D )i sap r o g r e s s i v e ,
X-linked, muscle-wasting disease that occurs in 1 in
3,500 live male births [1]. Males with inactivating muta-
tions in the DMD (dystrophin) gene make a nonfunc-
tional protein which results in degenerating skeletal
muscles, severely elevated creatine kinase (CK) levels,
cardiac arrhythmias and secondary infections and subse-
quent respiratory failure due to the degeneration of the
diaphragm muscles [2,3]. By contrast, patients with
Becker muscular dystrophy (BMD) also have mutations
in the DMD gene, but produce a partially functional
dystrophin protein [3]. Patients with BMD have mildly
progressive muscle weakness and elevated CK serum
levels as well as variable longevity and mobility [3].
While the genetic mutations that cause DMD are now
well established, the subsequent steps that lead to the
disease pathogenesis are still emerging [4]. In dystro-
phin-deficient muscles, it has been demonstrated that
the platelet-derived growth factor (PDGF) receptor
(PDGFR) signaling pathway is significantly altered [5,6].
Activation of PDGF signaling has been shown to pro-
mote the proliferation of myoblasts in primary myo-
blasts and C2C12 cultures [7]. PDGF signaling in skeletal
muscles goes through a phosphatase and tensin homo-
log deleted on chromosome 10/AKT (PTEN)/AKT sig-
naling pathway that is an important regulator of insulin
signaling and myoblast differentiation, proliferation and
cellular viability [8]. Recent studies in the mdx (dystro-
phin) mutant mouse model have found that mdx muscle
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addition, spontaneously occurring animal models of dys-
trophin deficiencies, such as the Golden Retriever mus-
cular dystrophy dog, have been found to have elevated
levels of PTEN within affected skeletal muscle fibers
[11]. Thus, in two animal models of dystrophin defi-
ciency, along with isolated biopsies from human DMD
patients, the upregulation of PTEN/AKT signaling has
been shown to be a secondary consequence of the lack
of a functional dystrophin protein resulting from an as
yet unclear mechanism.
Recently, we have shown that distinctive patterns of
microRNA (miRNA) expression are associated with dif-
ferent types of primary muscle disorders [12]. One parti-
cular miRNA, miR-486, was significantly reduced in
patients with DMD relative to control muscle biopsies.
Intriguingly, this miRNA was reduced relative to control
samples only in patients with DMD and not in those
with the milder but allelic BMD. miRNA are known to
be powerful regulators of multiple cell signaling path-
ways at critical time points in mammalian development
and differentiation. miRNA can downregulate gene
expression through either mRNA target degradation or
inhibition of mRNA translation at the ribosome [13]. In
skeletal muscle development, a series of muscle-enriched
miRNA control myoblast differentiation and overall
muscle strength and contraction [14].
Ankyrin 1 belongs to a family of proteins that contain
the ankyrin repeat domain, which is essential for cellular
membrane integrity and modulation of extracellular sig-
naling factors [15]. mIR-486 is transcribed within the
ANK1 (previously referred to as ankyrin-R) locus, from
which both erythroid and skeletal muscle-specific iso-
forms are transcribed [16]. The smaller isoform of the
ANK1 gene, ANK1.5 (also referred to as sANK1) contains
an alternately spliced, muscle-specific exon (exon 39A)
and lacks the characteristic ankyrin repeat domain
[16,17]. ANK1.5 is a small, skeletal muscle-specific pro-
tein that associates with the sarcoplasmic reticulum of
skeletal muscle myofibers [16,18]. Molecular interaction
experiments revealed that ANK1.5 interacts directly with
obscurin at the Z-disks of striated muscle fibers [19].
In a recent study, miR-486 was identified as a negative
regulator of PTEN expression levels in muscle and sub-
sequently in the PTEN/AKT pathway in normal cardiac
and skeletal muscle development [20]. Using computa-
tional bioinformatics, we identified additional miR-486
downstream targets in adult skeletal muscle: PDGFRb,
PIK3R1 (p85a) and insulin-like growth factor 1 (IGF-1).
Inhibition of miR-486 using a GFP-tagged lentivirus
impaired cellular migration to a scratch wound injury,
decreased myoblast fusion and increased cellular mitosis.
Conversely, overexpression of miR-486 resulted in faster
closure of the scratch wound, with no detrimental
cellular apoptosis, compared to a scrambled miRNA
control. Generation of muscle-specific miR-486-trans-
genic mice revealed perturbed muscle regeneration fol-
lowing cardiotoxin (CTX)-induced tibialis anterior (TA)
muscle injury and dysregulation of the downstream tar-
get genes of miR-486 in vivo. Together these studies
begin to characterize a functional role for miR-486 in
normal and dystrophin-deficient skeletal muscle and
further identify several components of the PTEN/AKT
signaling pathway as potential targets for miR-486 regu-
lation in muscle.
Results and Discussion
miRNA-486 expression is a significantly reduced miRNA in
dystrophin-deficient skeletal muscle
Previously, we identified a biosignature of miRNA that was
significantly dysregulated in human skeletal muscle biop-
sies taken from patients diagnosed with various muscular
disorders [12]. One particular miRNA, miR-486, was sig-
nificantly and specifically downregulated in DMD muscle,
but not in patients with BMD. miR-486 is highly con-
served among mammals and is embedded in the ANK1
gene locus within the intron between exons 41 and 42
(Figure 1A). Intriguingly, no miR-486 miRNA sequence
has been identified within the genomes of nonmammalian
species, such as fish or avians, although these species have
the Ank1 gene sequence. To validate the miRNA microar-
ray results indicating that miR-486 expression was signifi-
cantly reduced in DMD muscles relative to control
muscles, total miRNA was extracted from patients diag-
nosed with DMD or BMD or from normal controls (Fig-
ure 1B). Real-time quantitative PCR (qPCR) revealed that
miR-486 expression was significantly reduced in the mus-
cle biopsies from DMD patients, but not in those from
BMD patients with a fully or partially functioning dystro-
phin protein (n = 5 control biopsies, n = 5 DMD biopsies
and n = 3 BMD biopsies). In human myoblasts obtained
from normal and DMD biopsies, miR-486 was expressed
at similarly low levels early in myogenic differentiation
(Figure 1C). However, as normal skeletal myoblasts pro-
gress along myogenic differentiation to form mature myo-
tubes, miR-486 significantly increases until it reaches a
plateau at day 3 of differentiation. In contrast, DMD myo-
blasts exhibit a slight increase in the expression levels of
miR-486 during myogenic differentiation, but at signifi-
cantly reduced levels compared to normal myoblasts,
before miR-486’s expression decreases by day 4 of myo-
genic differentiation (Figure 1C).
In vivo skeletal muscle regeneration can be induced fol-
lowing CTX injury and is widely used to study factors
thought to be essential for new muscle fiber formation
[21]. Wild-type and mdx
5cv (dystrophin-deficient) mice
were injured in their TA muscles by injection of CTX.
This resulted in the destruction of up to 90% of myofibers
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Page 2 of 17followed by the regeneration of new myofibers (n = 3 mice
per time point for each cohort). Muscle biopsies from the
injured wild-type and mdx
5cv mice were harvested, and
total miRNA was extracted to determine whether the
levels of miR-486 were dynamically regulated during skele-
tal muscle regeneration. CTX injury was validated by H &
E staining of sections over the time course (representative
images obtained on days 0 and 14 are shown in Additional
file 1, Figure S1). In normal mouse muscle, miR-486
expression was significantly increased by day 5 after CTX
injury, which is when nascent myotubes begin to appear
[22,23] (Figure 1D). Conversely, mdx
5cv mice, which have
impaired skeletal muscle regeneration following CTX
injury [24], showed overall reduced levels of miR-486 dur-
ing skeletal muscle regeneration, which were statistically
significant (P < 0.005) at day 5 after CTX injury, when
there is maximum miR-486 expression in normal mouse
muscle (Figure 1D). Thus, miR-486 appears to be an
important miRNA that is dynamically regulated during
normal skeletal muscle regeneration, and its expression is
significantly reduced in mdx
5cv mice.
Inhibition of miR-486 in myoblasts and myotubes causes
profound physical and cellular changes
To identify what function miR-486 might play in normal
human myoblasts, we infected cells with a lentivirus that
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Figure 1 miR-486 is a highly conserved mammalian miRNA that is differentially expressed in DMD skeletal muscle. (A) miR-486 is
conserved across mammals and is under the transcriptional regulation of the ankyrin 1 locus. The ANK1.5 isoform has a unique start exon (exon
39A; blue) that is transcribed independently of the ANK1.1 isoform and lacks the ankyrin repeat domain. (B) miR-486 is significantly reduced in
DMD human skeletal muscle biopsies, but not in the milder BMD muscle biopsies, as compared to normal muscle controls. P = 0.03. The y-axis
represents mature miR-486 fold levels normalized to U6 snRNA housekeeping controls. Error bars indicate SEM. Normal biopsies: n = 5, DMD
biopsies: n = 5 and BMD biopsies: n =3 .(C) miR-486 is significantly upregulated during normal human myogenic differentiation, while the DMD
myoblasts express miR-486 at significantly lower levels. The y-axis represents mature miR-486 fold levels normalized to U6 snRNA loading
controls, and the x-axis represents the time of myogenic differentiation from 50% confluency (proliferating myoblasts) until day 4 differentiation
(multinucleated myotube formation). At 90% confluency (day 0 differentiation), myoblasts were exposed to differentiation medium (2% horse
serum). Blue lines represent normal human myoblasts, and red lines represent DMD myoblasts. (D) miR-486 is upregulated during skeletal
muscle regeneration following CTX-induced TA muscle injury. Blue lines indicate wild-type C57B6/J mice, and red bars indicate mdx
5cv mice. The
y-axis represents mature miR-486 fold levels normalized to U6 snRNA housekeeping controls. Error bars indicate SEM. *P < 0.005 and **P < 0.05.
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express a miR-486 inhibitor (anti-miR-486) or a
scrambled miRNA-negative control virus (Figure 2). All
viruses coexpressed an internal ribosome entry site
(IRES)-GFP tag as an indicator of positively infected
cells or myotubes. Myoblasts expressing either
scrambled miRNA or high levels of miR-486 showed no
visible physiological or significant structural differences
at both the myoblast and myotube stages of differentia-
tion (Figures 2A and 2B). However, in normal human
myoblasts in which miR-486 was inhibited, the myo-
blasts showed increased size and failed to flatten out as
they divided and expanded across the plate. Addition-
ally, myoblasts expressing the anti-miR-486 inhibitor
had reduced amounts of MF20
+ cells (myosin heavy
chain) as they began to elongate and fuse to form myo-
tubes (Figure 2D). Conversely, myoblasts that had
increased levels of miR-486 had significantly more
MF20
+ cells than the scrambled miRNA control infected
myoblasts (Figure 2D). Most myoblasts in which miR-
486 was inhibited showed little elongation and had
increased cellular size compared to those overexpressing
miR-486 and control infected myoblasts as quantified by
fluorescence-activated cell sorting (FACS) analysis (Fig-
ure 2E). By day 4 postinfection, the myotubes infected
with the miR-486 inhibitor virus began to break down
and form large cellular aggregates (inset in Figure 2B).
Therefore, in cell cultures, it appears that a reduction in
miR-486 levels results in myotube destruction analo-
gously to what may happen in the skeletal muscles of
DMD patients.
miR-486 is essential for normal myoblast fusion, cellular
kinetics and viability
To identify what effect manipulating miR-486 expression
levels in myoblasts and myotubes might have on cellular
kinetics, fusion and viability, miR-486 expression was
manipulated in both normal and DMD myoblast cell
lines. Both cell types were then assayed for various cellu-
lar markers of myoblast fusion index, cellular viability
and cell cycle kinetics. Normal human myoblasts showed
increased proliferation and a higher fusion index while
expressing higher levels of miR-486 at earlier time points
compared with scrambled miRNA controls. By day 2
postdifferentiation, the normal human myoblasts expres-
sing miR-486 had amounts of multinucleated myotubes
similar to those of the control scrambled miRNA myo-
blasts, whereas the anti-miR-486-expressing myoblasts
had significantly reduced amounts of multinucleated
myotubes (Figures 3A and 3B). When challenged with a
scratch wound assay, myoblasts infected with lentivirus
that caused overexpression of miR-486 migrated at a fas-
ter rate and closed the wound almost completely after 12
hours compared to control myoblasts expressing
scrambled miRNA (Additional file 2, Figure S2). Conver-
sely, myoblasts infected with a lentivirus anti-miR-486
inhibitor failed to migrate following the scratch wound
compared to scrambled miRNA controls (Additional file
2, Figure S2). These results suggest that miR-486 plays a
role in the migration of myoblast progenitor cells and
that alteration of miR-486 expression affects the signaling
pathways essential for cellular migration. To determine
the role that miR-486 might play in cellular viability, cas-
pase-3/7 levels were measured in myoblasts that either
overexpressed or knockdown miR-486 levels using a
luminescent reporter assay. Normal myoblasts expressing
high levels miR-486 showed no significant differences
compared to scrambled miRNA controls (Figure 3C).
However, inhibition of miR-486 in normal myoblasts
increased levels of caspase-3/7 and resulted in higher
levels of apoptosis. In DMD myoblasts, overexpression of
miR-486 again had little effect on cellular viability,
whereas inhibition of miR-486 resulted in increased cas-
pase-3/7 levels and thus increased cellular apoptosis (Fig-
ure 3C) (P < 0.05 for normal myoblasts and P < 0.005 for
DMD myoblasts). This correlates with previous studies of
DMD myoblasts in which researchers reported increased
levels of apoptosis in dystrophin-deficient muscles
marked by high caspase-3 levels [25]. Finally, we assayed
for the rate of proliferation of myoblasts by quantifying
the percentage of Ki-67
+ cells per 500 total positively
infected cells. Myoblasts expressing high miR-486 or
scrambled miRNA showed no differences in the percen-
tage of Ki-67
+ cells; however, both normal and DMD
anti-miR-486-expressing myoblasts showed reduced
amounts of Ki-67
+ cells (Figure 3D). These results imply
that inhibition of miR-486 has detrimental effects on the
ability of myoblasts to proliferate and maintain normal
cellular kinetics. miR-486 expression in myoblasts most
likely is expressed at a threshold level necessary for myo-
blast cellular viability, which is compromised in the
absence of a functional dystrophin protein.
miR-486 regulates a variety of PTEN/AKT signaling
components in skeletal muscle
To further examine the functional role of miR-486 in
normal and dystrophic muscles, we utilized several
bioinformatics software programs (TargetScan, http://
www.targetscan.org/; PicTar, http://pictar.mdc-berlin.de/
; and MicroCosm, http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5/) to identify those genes
whose expression might be altered by miR-486 expres-
sion. Among the list of potential genes possibly modu-
lated by miR-486 expression, only those that were
evolutionarily conserved across human and mouse gen-
omes were selected. An additional preference was given
to genes with known expression in skeletal muscle and/
or stem cells, as well as to genes previously
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Page 4 of 17Figure 2 Overexpression and inhibition of miR-486 causes profound cellular changes in myoblasts and myotubes. (A) Phase contrast
and GFP images of normal human myoblasts overexpressing miR-486, anti-miR-486 and a scrambled miRNA negative control virus are shown.
Note that the myoblasts overexpressing the miR-486 inhibitor (anti-miR-486) appear rounded and have not flattened out (inset). (B) Day 4
differentiated normal human myotubes infected with the same lentiviral vectors are shown. Note the aggregate of clumped myotubes (inset) in
cells infected with the anti-miR-486 lentivirus. (C) Higher magnification (×40) of normal human myoblasts infected with lentivirus expressing
scrambled miRNA, miR-486 and anti-miR-486. The cells show detection of the GFP reporter and 4’,6-diamidino-2-phenylindole (DAPI) to detect
the DNA. Note that the anti-miR-486-infected myoblasts are rounded (arrowheads) and increased in overall size compared to the scrambled
miRNA and miR-486-overexpressing myoblasts. (D) MF20 (red) staining of normal human myoblasts overexpressing scrambled miRNA, miR-486
or anti-miR-486 lentivirus. Chart indicates reduced levels of MF20
+ myoblasts that express anti-miR-486 lentivirus; conversely, myoblasts with high
levels of miR-486 have increased amounts of MF20
+ myoblasts. Ten fields of GFP-positive (not shown) and DAPI-positive cells were counted for
the presence of MF20
+ staining. Values were normalized to the scrambled miRNA. *P < 0.005 and **P < 0.05. Scale bar indicates 35 μm. (E) FACS
histogram reveals an increase in cell size in myoblasts infected with anti-miR-486 lentivirus. The x-axis represents forward scatter height (FSC-H),
and the y-axis represents the percentage cell size relative to the control scrambled miRNA myoblasts. FSC-H is quantified in the table that shows
that anti-miR-486 (blue line) have increased in cell size compared to myoblasts overexpressing miR-486 (green line) and scrambled miRNA
controls (red line). *P = 0.028 ± SEM.
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Page 5 of 17demonstrated to be significantly dysregulated in our pre-
vious dystrophin-deficient skeletal muscle microarray
analyses of RNA expression [10,26]. Several genes that
were possible targets for miR-486 were identified,
including PTEN, PDGFRb, FOXO1, IGF-1, PIK3R1
(p85a), SFSR1 and SFSR3 (Additional file 3, Figure S3).
The 3’UTR for each of the predicted transcripts that
contained these miR-486 binding sites were cloned into
a luciferase (luc) miRNA reporter (Figure 4A). These
3’UTR-luc constructs were transfected into human
embryonic kidney HEK293T cells along with constructs
that overexpress miR-486, scrambled miRNA (negative
control) plasmids or the vector alone. Overexpression of
miR-486 resulted in significant decreases in the lucifer-
ase activity in the PDGFRb-luc, PTEN-luc, PIK3R1-luc,
SFSR1-luc and SFSR3-luc reporter plasmids (Figure 4B).
FOXO1-luc levels were slightly decreased, but not at
statically significant levels (Figure 4B). Further validation
of these seed sites as binding sites for miR-486 was
done by mutating several conserved bases of the eight-
nucleotide seed site in the 3’UTR-luc reporters, which
resulted in restoration of luciferase levels to those of
scrambled miRNA and untransfected controls (Figure
4B). miRNA repression of genes can occur by either
mRNA degradation or inhibition of mRNA translation,
and it is necessary to measure the protein levels of
genes containing the miR-486 seed sites. To measure
the protein levels, normal human myoblasts were
infected with lentiviruses expressing miR-486 along with
an IRES-GFP reporter to indicate infection efficiency. In
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Figure 3 miR-486 is essential for normal myoblast fusion, cell cycle kinetics and viability in human skeletal myoblasts. (A) and (B)
Myoblast fusion assay reveals significantly lower fusion (shown as Fusion Index % of cells with 2 or more nuclei) in miR-486-inhibited (anti-miR-
486) cells. Normal and DMD myoblasts were infected at 50% confluency with lentivirus expressing miR-486, miR-486 inhibitor (anti-miR) or a
scrambled miRNA control virus and allowed to differentiate to 90% confluency. Note the decreased levels of fusion in both the normal and
DMD myoblasts at two time points (day 2 (Figure 2A) and day 4 (Figure 2B) of differentiation) when infected with anti-miR-486. (C) Increased
cellular apoptosis measured using a caspase 3/7 enzymatic assay in normal and DMD myoblasts overexpressing (miR-486) or inhibiting (anti-miR-
486) miR-486. DMD myoblasts overall had significantly higher caspase 3/7 activity compared with normal human myoblasts across all samples.
The y-axis indicates average RLUs (that is, caspase 3/7 activity), and the x-axis indicates the condition of the myoblasts. Mock and scrambled
miRNA-GFP-infected myoblasts served as negative controls (n = 3 replicates/cohort). Cells treated with hydrogen peroxide (H2O2) for 12 hours
served as positive controls. (D) Ki-67 levels measured by immunofluorescence in normal and DMD myoblasts which have increased miR-486
expression, reduced miR-486 expression or expression of scrambled miRNA (negative control). Note the decreased levels of Ki-67 in myoblasts in
which miR-486 expression is knocked down. *P < 0.005 and **P < 0.05 for comparisons between scrambled miRNA (control) versus miR-486-
and/or anti-miR-486-infected myoblasts.
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Page 6 of 17addition, all miR-486 targets were verified at the protein
level by Western blot analysis. Overexpression of miR-
486 resulted in significantly decreased protein levels of
PTEN, PDGFRb,F O X O 1 ,S F S R 1a n dS F S R 3( F i g u r e
4C). Several of these proteins comprise the PTEN/AKT
pathway, which is essential for normal cellular prolifera-
tion through the regulation of the critical cyclin-depen-
dent kinase inhibitors CDKN1A (p21) and CDKN1B
(p27) through FOXO1-dependent transcriptional regula-
tion [27,28]. Overexpression of miR-486 in myoblasts
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Figure 4 Members of the PTEN/AKT signaling pathway and splicing factors are direct downstream targets of miR-486 in skeletal
muscle. (A) Schematic shows the location of the 3’UTR miR-486 target cloned downstream of the luciferase gene reporter with a poly(A) tail.
(B) Luciferase miRNA reporter assay of several of the 3’UTR of the predicted miR-486 direct downstream targets. The lower graph shows results
from the mutation of the miR-486 seed site, which ablates miR-486 binding and functions to derepress luciferase expression. The y-axis displays
relative RLU activity normalized to 100% activation of the reporter transfected alone (vector alone). Error bars indicate SEM (n = 3 replicates, with
the experiment performed on three separate occasions using HEK293T cells). *P < 0.005 and **P < 0.05. (C) Western blots of myoblasts
overexpressing miR-486 or scrambled miRNA controls. Anti-b-tubulin served as a loading control. Western blot analysis of alternately splicing
factors SFRS1 and SFRS3 was performed from myotube lysates from which both proteins are most abundantly expressed.
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p27 (Figure 4C). Given that miRNA are known to regu-
late several components in the same pathway, it seems
likely that miR-486 acts on the p21/FOXO1 pathway
through its primary regulation of the PTEN/AKT
pathway.
Transgenic mice expressing miR-486 have impaired
skeletal muscle regeneration following CTX injury
To characterize miR-486 function in vivo, transgenic
mice that overexpress miR-486 transcript at levels
greater than twofold compared to their wild-type con-
trol littermates were generated (Figure 5A). To develop
t h e s em i c e ,aD N Ac o n s t r u c t containing the mouse
miR-486 genomic sequence was cloned downstream of
the muscle CK (MCK) enhancer element, which is
expressed exclusively in the heart and skeletal muscle
myofibers, thus excluding muscle satellite cells [29]. The
MCK miR-486-transgenic (miR-486-Tg) mice were
viable and displayed no overt phenotypic differences
from their wild-type littermate controls at six months of
age, other than a slight increase in weight that was
maintained for the remainder of their lifespan (Figure
5B). To test whether increased expression of miR-486
would influence in vivo regeneration of muscle, similar
to our observations in cell culture, the miR-486-Tg mice
were injected with CTX and their regenerative capacity
was compared to the injured muscles of their wild-type
littermates. At seven days postinjury, compared to wild-
type day 7 CTX controls, the muscles of the miR-486-
Tg mice had failed to fully regenerate and had accumu-
lations of myonuclei (Figu r e5 C ) .B yd a y1 4p o s t - C T X
injury, the miR-486-Tg mice had recovered their muscle
fiber architecture, but many centralized, multinucleated
myofibers remained, whereas significantly fewer centra-
lized myonuclei were observed in the day 14 wild-type
controls (Figure 5D). Immunofluorescent (IF) staining of
the proliferation marker Ki-67 revealed that the miR-
486-Tg mice had significantly higher amounts of Ki-67
+
cells at days 7 and 14 post-CTX injury compared to
their wild-type controls (Additional file 4, Figure S4).
Together these results implicate a delay in skeletal mus-
cle regenerative capacity in mice that maintain increased
miR-486 levels and further implicate miR-486 as a
potential indirect regulator of muscle satellite cell
kinetics and fusion capabilities during muscle
regeneration.
Transgenic mice overexpressing miR-486 have altered
levels of PTEN/AKT signaling components during skeletal
muscle regeneration
To fully evaluate the functional role of miR-486 in vivo
by real-time qPCR, the CTX-injured TA muscles of
miR-486-transgenic and wild-type mice were used to
measure the expression levels of genes known to be cri-
tical components of the PTEN/AKT pathway. The miR-
486-transgenic mice showed significantly decreased
mRNA expression of the miR-486 downstream target
genes (mRNA for Pdgfrb and Foxo1) in their skeletal
muscles at specific time points during days 3 through 7
post-CTX injury as would be expected if these genes
were direct miR-486 targets (Figure 6). Pik3r1 showed
decreased mRNA expression on days 5 through 14 post-
CTX-induced injury, but not at significant levels. Pten
levels remained reduced in the uninjured (day 0) miR-
486-Tg muscles and at day 3 of muscle regeneration
(Figure 6). The Forkhead transcription factor Foxo1 is
the downstream target of PTEN/AKT signaling and reg-
ulates the cell cycle through transcriptional activation of
several cyclin-dependent kinase inhibitors (such as p21
and p27) in many cell types, including skeletal muscle
[28,30,31] (Figure 6). At the same critical time point
during skeletal muscle injury (days 3 through 5) in the
miR-486-Tg mice, there was a reduction in the levels of
the Foxo1 targets p21 and p27, but not p57 (Figure 6
and Additional file 5, Figure S5), which is not a direct
target of Foxo1 signaling [32] but has been shown to
play an essential role in skeletal muscle formation [33].
Additionally, several Foxo1-interacting factors regulating
cellular viability, such as Bcl2, Bax and Bim,s h o w e d
slight modulations in gene expression during the same
critical time points (days 3 through 7 post-CTX injury)
during skeletal muscle regeneration (Additional file 5,
Figure S5). Together these studies implicate miR-486 as
a negative regulator of the PTEN/AKT signaling compo-
nents and their downstream effector proteins in vivo
during skeletal muscle regeneration.
Conclusions
In summary, these studies identify miR-486 as a
uniquely downregulated miRNA in DMD. With many
targets of miR-486 residing in the PTEN/AKT signaling
pathway (both upstream and downstream), it is likely
that miR-486 functions as a regulator of cell cycle
kinetics, cell cycle viability and perhaps cellular migra-
tion in skeletal muscle (Figure 7). Additionally, our iden-
tification of miR-486 as a potent repressor of several
components of the PTEN/AKT signaling pathway fol-
lows, as many of these signaling components are shown
to be upregulated in DMD muscle while miR-486 is
expressed at reduced levels. Another recent study profil-
ing dysregulated miRNA in mdx mouse muscle demon-
strated that the lack of dystrophin resulted in the
dysregulation of several miRNA, including miR-486,
which further validates our findings that miR-486 is
reduced in the absence of a functional dystrophin.
Although the mdx
5cv mutant mouse has a less severe
phenotype than that observed in human DMD patients,
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Figure 5 Transgenic miR-486 overexpression in mice results in abnormal skeletal muscle regeneration following CTX-induced TA
injury. (A) Diagram indicating the construct used to generate MCK-miR-486-transgenic mice. Real-time qPCR of miR-486 expression levels in the
TA muscle was analyzed from three separate wild-type (black bars) and miR-486 Tg (red bars) adult mice. Expression levels were normalized to
U6 snRNA levels and compared to wild-type (control) levels. (B) Mouse weights of wild-type and miR-486 Tg mice versus age (in months) are
shown. Three mouse cohorts of male and female littermates were weighed from 1, 3, 6, 9, 12 and 15 months of age (n = 5 male or female mice
per cohort). *P < 0.005 and **P < 0.05. (C) H & E-stained histological sections of wild-type and miR-486 Tg mice on day 0 (uninjured), 7 and 14
post-CTX-induced TA injury. Arrowheads indicate centralized myonuclei. Scale bars = 20 μm. (D) Percentages of total centralized myonuclei
during CTX-induced TA injury in wild-type and miR-486 Tg mice. Percentages are based on counts of 200 myofibers in three separate mice per
cohort at three time points (0, 7 and 14 days post-CTX injury). *P < 0.005 and **P < 0.05.
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Page 9 of 17it contains frame shift mutations resulting from an A to
T transversion in exon 10 of the dystrophin gene that
results in a 53-bp deletion sequence starting from exon
10 and does not produce the large Dp427 skeletal mus-
cle isoform [34]. Thus, one might hypothesize that the
presence of the large Dp427 skeletal muscle isoform is
essential for maintaining normal miR-486 expression
levels, especially since BMD patients with a partially
functional truncated dystrophin protein [3] have normal
miR-486 regulation in muscle, which we have validated
in this study.
miR-486 has also been shown to be dysregulated in
three other pathological conditions: white blood cells
during sepsis, glioblastomas and lung adenocarcinomas
[35-37]. Many cancers have been shown to have dysre-
gulated PTEN/AKT signaling resulting from a failure to
regulate normal cell cycle kinetics and cellular apoptosis
[38,39]. miR-486’s influence on cell cycle progression
through the regulation of PTEN/AKT signaling compo-
nents and their subsequent downstream regulation of
cyclin-dependent kinase inhibitors reinforces the role of
miR-486 as a biomarker in several cancers. In cardio-
myocytes, miR-486 has been shown to be a negative reg-
ulator of PTEN/AKT signaling during heart ventricle
postnatal development [20]. That study also demon-
strated that miR-486 expression can be activated by
myocardin-related transcription factor A (MRTF-A, also
referred to as MAL/MKL1) [20], a coregulator of the
serum response transcription factor, which has been
shown to regulate actin polymerization and Rho signal-
ing in cardiac hypertrophy [40,41]. Although MRTF-A
has been studied predominately for its role in cardiac
hypertrophy and heart failure, it is expressed in C2C12
myoblasts and may be essential for normal myogenic
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Figure 6 miR-486 overexpression regulates skeletal muscle PTEN/AKT signaling in vivo. Real-time qPCR measuring levels of Pdgfrb, Pten,
Foxo1, Pik3r1 (p85a), p21 (Cdkn1a) and p27 (Cdkn1b) in mouse skeletal muscle during the time course of skeletal muscle regeneration (day 0
(uninjured) to day 14 post-CTX TA injection) in wild-type (black bars) and miR-486 Tg (green bars) mice. Three muscles per time point per day of
injury were analyzed in triplicate. Error bars indicate SEM. Relative mRNA expression levels were normalized to 18 s ribosome (18sRib) loading
control and day 0 (uninjured) wild-type muscle. *P < 0.05 wild-type vs. miR-486 Tg values.
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Page 10 of 17differentiation. Additionally, MRTF-A may have a func-
tion in skeletal muscle hypertrophy and atrophy through
a striated activator of Rho signaling-dependent pathway
[42,43]. Another recent study identified miR-486 along
with miR-206 (another muscle-enriched miRNA) as a
regulator of myoblast cell cycle kinetics through its
downregulation of Pax7 mRNA and another muscle-
enriched miRNA, miR-206 [44]. However, given that
miR-486 expression is activ a t e db ym y o g e n i cf a c t o r s
that are downstream of Pax7 (such as MyoD1), it is
likely that miR-486’s regulation of PTEN/AKT signaling
might explain the cell cycle defects due to the Pax7
+
low expression in MyoD1
+ myoblasts [45,46].
miR-486 may also have important regulatory functions
that are independent of PTEN/AKT signaling in other
cell types and pathological diseases. Recently, miR-486
has been found to be significantly upregulated in lym-
phoblast cell lines derived from autistic patients [47].
Intriguingly, patients with DMD have an increased inci-
dence of autism or other neurological disorders [48,49].
Given that two of the components that are essential for
normal alternative splicing of mRNA (splicing factor,
arginine/serine-rich 1 (SFRS1) and SFRS3) are likely tar-
gets of miR-486, it is possible that miR-486 could play a
role in the translation of genes essential for normal cel-
lular homeostasis in other tissues, such as the brain.
These studies offer a possible mechanism for the
upregulation of PTEN/AKT signaling pathway compo-
nents, which have previously been observed in dystro-
phin-deficient skeletal muscle. Recently, it has been
shown that mice lacking PTEN had improved skeletal
muscle regeneration when fed a high-fat diet [50]. Mod-
ulation of the PTEN/AKT signaling pathway through
miR-486 expression has the potential to be a novel ther-
apy for treating DMD. Delivery of miR-486 in skeletal
muscle might have a beneficial effect in ameliorating the
secondary signaling defects that are observed in dystro-
phin-deficient muscle. Advances in the use of stable in
vivo exon-skipping morpholinos for the correction of
out-of-frame DMD gene mutations and deletions have
led to an increased interest in the use of nonintegrative
methods for the treatment of DMD [51,52]. One can
envision that a combination therapy involving the over-
expression of intramuscular injection of stabilized miR-
486 along with exon-skipping morpholinos might
restore muscle function and prevent some of the muscle
loss observed in DMD patients.
Materials and methods
Human biopsies and establishment of primary myoblast
cell lines
DMD/BMD patient muscle tissue was obtained during
either diagnostic skeletal muscle biopsies or other clini-
cal surgeries. Control muscle tissue was obtained from
patients undergoing clinical orthopedic surgery. Each
biopsy sample was divided into two either to be frozen
for sectioning or to be used to establish myoblast cul-
tures. All patients were males between 6 and 65 years of
age and were classified as normal, DMD or BMD based
on a combination of DNA sequencing, dystrophin pro-
tein analysis by Western blotting and physician evalua-
tion. The muscle groups biopsied were from human TA,
back (latissimus dorsi) or hip muscles (vastus lateralis),
depending on tissue availability. Mutations in the DMD
gene locus were validated by the clinical DNA Diagnos-
tic Center at Children’s Hospital Boston by both South-
ern blot analysis and automated sequencing analysis
using universal conditions for direct sequencing meth-
ods [53]. All BMD samples contained separate deletions
residing in exons 45 through 49 of the dystrophin gene
(patient 1, exons 45 through 48 deleted; patient 2, exons
48 and 49 deleted; and patient 3, exons 45 through 49
deleted), which resulted in a truncated but partially
functional dystrophin protein. All BMD muscle biopsies
were analyzed by Western blotting and were determined
to have truncated dystrophin protein (Dp427) molecular
weights that ranged from 380 and 402 kDa. All patients
gave their written and oral consent prior to surgery, and
all protocols were approved by the Children’s Hospital
Boston human subjects internal review board (protocol
03-12-205R).
Myoblasts were isolated from fresh biopsies by first
washing the samples in ice-cold 1× PBS and then min-
cing them with sterile scalpels on a 100-mm plate for
10 minutes until all clumps were removed. The minced
muscles were then incubated with a collagenase IV neu-
tral protease (Worthington Biochemical Corp.
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Figure 7 miR-486 is an important regulator of PTEN/AKT
signaling in normal and dystrophic muscle. Schematic of miR-
486 regulation of PTEN/AKT pathway upstream and downstream
signaling components in skeletal muscle is shown. Regulation of the
PTEN/AKT pathway in turn regulates FOXO1, which is a well-
characterized regulator of p21 and p27 in skeletal muscle.
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Page 11 of 17Lakewood, NJ, USA) at a ratio of 3.5× the gram weight
of the minced muscle. The plate was incubated at 37°C
for 45 minutes until the cells were in suspension by
pipetting the mixture thrice at 15-minute intervals. Ten
milliliters of human skeletal muscle growth medium
(PromoCell, Heidelberg, Germany) were added to the
mixture. The mixture of cells was then passed through a
70-μm filter and centrifuged at 514 × g at 4°C for 10
minutes. The supernatant was aspirated, and then the
cells were resuspended in red blood cell lysis buffer
(Qiagen, Valencia, CA, USA) and incubated for three
minutes at room temperature. Following incubation, 22
mL of growth medium were added to the cells, followed
by a second filtration using a 40-μm filter. The filtrate
was then centrifuged at 514 × g at 4°C for 10 minutes.
The supernatant was aspirated, and then the cells were
resuspended in 10 mL of growth medium before being
seeded onto uncoated 100-mm plates for one hour in a
37°C incubator. Following the one-hour preplating on
uncoated plates, the supernatants containing unattached
cells enriched for myoblasts were replated onto 0.1%
gelatin-coated 100-mm plates (porcine; Sigma-Aldrich,
St Louis, MO, USA). Cells were passaged every two to
three days. Additionally, the cells were subjected to at
least two additional preplating steps in which the fibro-
blasts adhered to the uncoated dishes and the slowly
adhering myoblast fraction was then plated onto the
gelatin-coated dishes, similarly to a protocol described
previously [54]. Myoblast enrichment was measured by
immunofluorescent labeling of cells using a desmin anti-
body (1:500 dilution; Epitomics Inc., Burlingame CA,
USA). Cellular preparations that contained over 90%
desmin-positive myoblasts were considered “myoblast
enriched” and thus were appropriate for cell culture
experiments.
Lentivirus production
Lentivirus vectors that stably overexpress a pre-miR-486
precursor, anti-miR-486 (miRZipsSystem Biosciences
Inc., Mountain View, CA, USA) or scrambled miRNA
(nonsense small hairpin RNA) controls that contained
bicistronic IRES-GFP tags were obtained commercially
(System Biosciences Inc., Mountain View, CA, USA).
Third-generation lentiviral packaging plasmids (MDL/
RRE, Rev and VSV-G) were a generous gift from GQ
Daley (Children’s Hospital Boston) [55]. HEK293T cells
w e r eg r o w ni n1 0 0 - m mp l a t e si n1 0 %f e t a lb o v i n e
serum (FBS)/DMEM (Mediatech Inc., Manassas, VA,
USA) supplemented with 1× antibiotics (Invitrogen,
Carlsbad, CA, USA). Lentiviral vectors along with packa-
ging plasmids were transfected in ten 10-cm plates (at a
ratio of 3 μg lentiviral vector to 1 μg of each packaging
plasmid per 10-cm plate) containing 90% confluent
HEK293T cells using Lipofectamine 2000 reagent
(Invitrogen). Three days after transfection viral superna-
tants were pooled and filtered through 45-μmf i l t e r s
(VWR International LLC., Radnor, PA, USA), mixed
with a 1/3
rd volume of Lenti-X lentivirus concentrator
(Clontech Laboratories Inc., Mountain View, CA, USA)
and incubated overnight at 4°C. The following day the
lentiviral concentrate elute was pelleted by centrifuga-
tion at 1,500 × g for 45 minutes at 4°C. Viral pellets
were resuspended in DMEM at one-twentieth the start-
ing volume. The lentiviruses were titered by calculating
the percentage of GFP fluorescence to the total number
of plated cells in subsequent tenfold serial dilutions fol-
lowing infection of 500,000 HEK293T cells [56]. Most
lentiviral infections were done at a viral titer of approxi-
mately 2 × 10
8 TU/mL.
Mouse lines
C57BL6/J wild-type control mice and mdx
5cv mice were
purchased from Jackson Laboratories (Bar Harbor, ME,
USA) [57]. All mouse husbandry and transgenic lines
were approved by the Children’s Hospital Boston Ani-
mal Facilities/Institutional Animal Care and Use Com-
mittee and maintained in pathogen-free cages following
federal standard of care practices. Individual mice were
weighed on a Denver Instrument DLT Series scale
(Denver Instrument, Bohemia, NY, USA All mice were
fed a 5P00 Prolab RMH 3000 standard chow diet (5%
fat; LabDiet, PMI Nutrition International, St. Paul, MN,
USA;) and had access to food ad libitum.A l lm o u s e
lines and subsequent breeding were maintained on a
C57BL6/J background under the Children’sH o s p i t a l
Boston ARCH animal protocol (10-12-1852R).
The MCK-miR-486-Tg overexpression mouse lines
were generated using the pBS-MCK backbone plasmid
obtained from Addgene (plasmid 12528; Addgene, Cam-
bridge, MA, USA). The MCK plasmid contains a 6-kb
enhancer region for the mouse muscle creatine kinase
Ckm gene and has been previously characterized [29,58].
A 500-bp fragment containing the stem loop precursor
sequence of mouse miR-486 was amplified by PCR from
C57BL6/J mouse genomic DNA and subcloned into the
PstI/SpeI restriction sites of the pBS-MCK plasmid. The
6-kb MCK fragment plus the miR-486 sequence and a
simian virus 40 (SV40) polyadenylation (poly(A)) signal
w e r ee x c i s e df r o mt h ep l a s m i du s i n gKpnI/SacIr e s t r i c -
tion enzymes. Following DNA purification using the
GeneClean II kit (MP Biomedicals LLC, Solon, OH,
USA), the linearized DNA fragment was then injected
into the pronucleus of C57BL6/J fertilized eggs and
transplanted into the uterine horn of pseudopregnant
ICR foster mice. A total of 55 viable pups from five
separate injections were genotyped by PCR using pri-
mers specific for the MCK enhancer element and the
SV40 poly(A) signal transduction sequence. All F0
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ground. Additional mouse genotyping was performed
commercially by Transnetyx, Inc. (Cordova, TN, USA).
Additional cell cultures
HEK293T cells were a generous gift from the laboratory
of GQ Daley (Children’s Hospital Boston). The cells
were maintained using 10% FBS (Atlanta Biologicals
Inc., Lawrenceville, GA, USA)/DMEM (Invitrogen) sup-
plemented with antibiotics (Antibiotic-Antimycotic;
Invitrogen) as described previously [55].
miRNA isolation and real-time qPCR
miRNA and mRNA were extracted from either cell lines
or animal tissue using the miRVana Isolation kit
(Ambion Austin, TX, USA). Fifty nanograms of total
enriched miRNA per sample were copied into cDNA
(through RT) using the Multiscribe RT System (Applied
Biosystems Carlsbad, CA, USA). One microliter of RT
reaction was used for each specific miRNA TaqMan
assay (Applied Biosystems), which was amplified using
No-Amp Erase TaqMan Polymerase (Applied Biosys-
tems) according to the manufacturer’si n s t r u c t i o n s .A l l
samples were analyzed in 96-well optical plates on an
ABI 7900HT real-time PCR machine (Applied Biosys-
tems). Cycle times were normalized to U6 small nuclear
RNA as a loading control. Relative fold expression and
changes were calculated using the 2
-ΔΔCt method [59].
Total RNA from muscle biopsies and cell cultures
was extracted using the mirVana miRNA/mRNA Isola-
tion Kit (Ambion). One microgram of total RNA was
copied into cDNA using the First-Strand cDNA Synth-
esis Kit (Invitrogen). Tenfold serial dilutions of cDNA
were analyzed on 96-well optical plates using Power
SYBR Green Master Mix (Applied Biosystems) and
analyzed on the ABI 7900HT real-time PCR machine.
Primers specific for each gene were designed using
National Center for Biotechnology Information Primer-
Blast http://www.ncbi.nlm.nih.gov/tools/primer-blast/
index.cgi?LINK_LOC=BlastHome, and all cycle time
values were normalized to an 18 s ribosome loading
control. All real-time qPCR primers are listed in Addi-
tional file 6, Table S1.
Antisera
T h ef o l l o w i n gp r i m a r ya n t i b o d i e sw e r eu s e di nt h i s
study: anti-GFP (1:1,000 dilution Western blot; MBL
International Corp. Woburn, MA, USA; and 1:50 dilu-
tion IF; Chemicon International Temecula, CA, USA),
anti-b-tubulin horseradish peroxidase (HRP) (1:1,000
dilution Western blot; Cell Signaling Technology Dan-
vers, MA, USA), anti-PTEN (1:1,000 dilution Western
blot; Cell Signaling Technology), anti-PDGFRb (1:1,000
dilution Western blot; Bioworld Technology Inc. St.
Louis Park, MN, USA), anti-PIK3R1 (1:1,000 dilution
Western blot; Abcam), anti-FOXO1 (C29H4 clone,
1:1,000 dilution Western blot; Cell Signaling Technol-
ogy), anti-SFRS1 (1:1,000 dilution Western blot; Aviva
Systems Biology San Diego, CA, USA), anti-SFRS3
(clone 2D2, 1:1,000 dilution Western blot; Sigma-
Aldrich), anti-MF20 (1:25 dilution IF; Developmental
Studies Hybridoma Bank, Iowa City, IA, USA); anti-Ki-
67 (1:200 dilution IF; BD Pharmingen Inc., San Diego,
CA, USA), anti-desmin (1:1,000 dilution IF Epitomics
Inc. Burlingame CA, USA;), anti-p21 (1:1,000 dilution
Western blot; Abcam) and anti-p27 (1:500 dilution Wes-
tern blot; Abcam). Secondary antibodies used for Wes-
tern blot analysis included anti-mouse and anti-rabbit
HRP-conjugated antibodies (1:2,000 dilution Western
blot; Cell Signaling Technology), along with anti-goat
HRP-conjugated antibody (1:1,000 dilution Western
blot; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Secondary antibodies (Invitrogen) were used for immu-
nofluorescent detection of primary antisera in mouse
and rabbit with Alexa Fluor fluorochromes conjugated
at 488 nm and 565 nm.
FACS analysis
Myoblasts were sorted using FACS analysis for detection
of the IRES-GFP reporter indicating a positively infected
cell and were stained with propidium iodide (2 μg/mL;
BD Biosciences San Jose, CA, USA) to exclude dead
cells. The myoblasts were sorted on a FACSVantage
flow cytometer (BD Biosciences), and all FACS plots
were analyzed using FloJo version 6.4.7 software (Tree
Star, Inc., Ashland, OR, USA).
Western blot analysis
All protein preparations were quantified using a bicinch-
oninic acid protein assay kit (Pierce Biotechnology
Rockford, IL, USA). Thirty micrograms of whole cell
protein lysate were resolved on 4% to 20% gradient
Tris-acetate gels (Invitrogen). Following transfer to poly-
vinylidene fluoride (PVDF) membranes (Invitrogen), the
membranes were blocked with 5% nonfat milk (Cell Sig-
naling Technology)/Tris-buffered saline (TBS)-Tween 20
(Sigma-Aldrich) before being incubated overnight at 4°C
with primary antisera diluted in 5% milk/TBS-Tween 20
(Boston BioProducts Inc., Ashland, MA, USA). The
membranes were subjected to a series of three TBS-
Tween 20 washes. The secondary HRP-conjugated anti-
bodies were diluted in 5% milk/TBS-Tween 20 prior to
being incubated with PVDF membranes (Invitrogen) for
one hour at room temperature. Following additional
washes prior to application of chemiluminescent sub-
strate (Millipore, Billerica, MA, USA), the membranes
were exposed on Kodak BioMax film (Sigma-Aldrich)
using varying exposure times.
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Four-month-old male C57BL6/J and miR-486-Tg litter-
mate mice were subjected to injections into their TA
muscles with 10 μM CTX (C9759; Sigma-Aldrich) that
was resuspended in 1× PBS. Another cohort received 1×
PBS sham (no CTX) control TA injections. All mice
were monitored for signs of pain or distress following
the injections. The mice were killed by CO2 asphyxia-
tion, and their muscles were harvested at 0 (uninjured),
1, 3, 5, 7 and 14 days post-CTX injury. The harvested
muscle biopsies were then embedded in Tissue-Tek O.
C.T. compound (Sakura Finetek U.S.A. Inc., Torrance,
CA, USA) and snap-frozen in liquid nitrogen chilled in
isopentane (Sigma-Aldrich). The frozen muscles were
then cryoembedded and sectioned on a cryostat in 7-
μm-thick sections. A portion of each muscle was har-
vested for total RNA extraction at a later time point.
The muscle sections were then placed on polylysine
slides. Sections were methanol-fixed for 3 minutes at
-20°C and then stained with H & E (Sigma-Aldrich) to
observe morphology. Sections were imaged on a Nikon
Eclipse E1000 microscope (Nikon Instruments, Melville,
NY, USA using SPOT imaging software (SPOT Imaging
Solutions, Sterling Heights, MI, USA).S o m ei m a g e s
were later modified using Adobe PhotoShop and Adobe
Illustrator CS4 (Adobe Systems Inc., San Jose, CA, USA
to enhance image resolution and add scale bars.
Myoblast wound migration assay
Primary human myoblasts were seeded onto 0.1% gelatin-
coated 20-mm two-well chamber slides at 25,000 cells/
well. Twenty-four hours later the cells were infected with
lentivirus or a 1× PBS mock control at 10 multiplicities of
infection. Twenty-four hours postinfection the cell wells
were scratched vertically with a P100 pipette. The cells
were at 85% to 90% confluence at the time of the scratch
wound. Cell migration was measured at 0, 12 and 24
hours. By 24 hours, all but the anti-miR-486-infected cells
had fully migrated to close the scratch wound (data not
shown). All scratch wounds were performed in triplicate.
Each group of infected cells was fixed at each of the
time points with 4% paraformaldehyde for 10 minutes at
4°C with gentile agitation. Following fixation the cells
were washed twice in 1× PBS and three times in 0.1%
Triton X-100/1× PBS, and then they were incubated in
blocking buffer (10% horse serum (Gibco, Grand Island,
NY, USA) and 0.1% Triton X-100 (Sigma-Aldrich)
m i x e di n1 ×P B S ,M e d i a t e c h ,I n c .M a n a s s a s ,V A ,U S A )
for one hour at room temperature with light shaking.
Following blocking the cells were incubated with phal-
loidin conjugated to Alexa Fluor 546 (1:100 dilution in
blocking buffer; Invitrogen) overnight at 4°C with gentle
shaking. Cells were then washed three times with 0.1%
Triton X-100/1× PBS before being mounted with VEC-
TASHIELD mounting medium containing 4’,6-diami-
dino-2-phenylindole (DAPI) (Vector Labs, Burlingame,
CA, USA). Cells that had been stained were photo-
graphed with a Nikon II(Nikon Instruments, Melville,
NY, USA;) microscope using SPOT imaging software
(SPOT Imaging Solutions, Sterling Heights, MI, USA) at
all three time points.
miRNA reporter assays
Following prediction of the transcripts which were
thought to be targets of miR-486, the 3’UTR regions of
these genes were amplified by PCR from a human total
mRNA library (Ambion) or from commercially cloned
constructs (GeneCopoeia Inc., Rockville, MD, USA).
The 3’UTR amplicons were then cloned into the SpeI
and NotI restriction sites of a modified version of the
pGL2Basic vector containing a novel multicloning site
from the pCR4-TOPO vector (Invitrogen) between the
luciferase open-reading frame and the SV40 poly(A) sig-
nal (gift from A Dostal, J Ho and JA Kreidberg; Chil-
dren’s Hospital Boston).
The miRNA 3’UTR-luc reporter assay was performed
by first plating 20,000 HEK293T cells/well into 48-well
plates. The following day the cells were transfected
using Lipofectamine 2000 reagent with 30 ng of 3’UTR
miRNA-luc reporter constructs and 100 ng of miR-486
overexpression plasmid (Origene, Rockville, MD, USA);
pCMVmiR-IRES-GFP vector) or scrambled miRNA con-
trols (Origene). Forty-eight hours after transfection the
cells were lysed in radioimmunoprecipitation assay buf-
fer (Thermo Fisher Scientific Inc., Waltham, MA, USA),
and 20 μL of whole cell lysate were assayed with 50 μL
of luciferase substrate using the Dual Reporter Assay
(Promega, Madison, WI, USA). Luciferase levels were
measured on a single-tube luminometer (Berthold Tech-
nologies USA, LLC., Oak Ridge, TN, USA). The seed
sites in the 3’UTR-luc reporters were mutated from
GTACAGG to GgAaAtG using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA).
CASPASE 3/7 assays
Twenty-five microliters of total protein lysates from
infected normal and DMD myoblasts were incubated
with 100 μL of Caspase-Glo 3/7 reagent (Promega)
according to the manufacturer’s protocol. Luciferase
measurements were taken on a single-tube luminometer
(Berthold Technologies).
Statistical analysis
Unless otherwise stated, all statistical analyses were per-
formed using a Student’s t-test (two-tailed).
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Additional file 1: Supplemental Figure S1. Regeneration of wild-
type and mdx
5cv murine skeletal muscle following the delivery of
CTX to TA muscles. H & E staining of wild-type and mdx
5cv adult mouse
TA sections of CTX-injured muscles, with uninjured TA muscles serving as
controls (n = 3 muscles/cohort). Scale bars = 20 μm. Note the impaired
differentiation and large numbers of centralized myonuclei (black
arrowheads) in the mdx
5cv mice compared to their wild-type control
cohorts.
Additional file 2: Supplemental Figure S2. miR-486 expression is
essential for normal myoblast migration and wound closure. Normal
human myoblasts overexpressing lentiviral miR-486-GFP migrate faster to
close the scratch wound compared with scrambled miRNA-GFP (negative
control) 12 hours post-scratch wound. Myoblasts overexpressing lentiviral
anti-miR-486-GFP fail to migrate to close the wound 12 hours post-
scratch infliction. Top panel shows the initial scratch wound at 0 hours in
phase contrast and GFP (green) fluorescence, which serves as an
indicator of viral infection efficiency. Bottom panel shows myoblast
wound closure 12 hours post-scratch wound in phase contrast and
stained with phalloidin (red) and DAPI (DNA; blue). Representative scale
bars show the diameters of the scratch wound in micrometers.
Additional file 3: Supplemental Figure S3. Evolutionary
conservation between human and mouse seed regions of predicted
miR-486 downstream target genes. Several components of the PTEN/
AKT signaling pathway are predicted targets of miR-486 in mammals
(human and mouse). Shown are nine highly evolutionarily conserved
miR-486 seed sites located within seven different genes: PDGFRb, FOXO1,
PTEN, IGF-1, PIK3R1 (p85a), SFRS1 and SFRS3. miR-486 alignment is 3’ to 5’,
and the miR-486 binding site is 5’ to 3’.
Additional file 4: Supplemental Figure S4. Mice that overexpress
miR-486 in their muscles have increased amounts of Ki-67
+ cells
during skeletal muscle regeneration. Immunofluorescent staining of
skeletal muscle from wild-type (WT) and miR-486 Tg mice at day 0
(uninjured), day 7 and day 14 post-CTX-induced TA injury. The graph
denotes increased levels of Ki-67
+ myogenic cells in the miR-486 Tg mice
at days 7 and 14 post-CTX-induced TA injury. The Ki-67
+ cells were
counted based on averages taken from ten separate fields. The sections
were stained with desmin (red) and Ki-67 (green) antibodies. Arrowheads
indicate Ki-67
+ cells in a given field, and scale bars indicate 40 μmi n
length. All images were obtained at ×40 magnification. *P < 0.005 and
**P < 0.05 wild-type vs. miR-486 Tg.
Additional file 5: Supplemental Figure S5. miR-486 overexpression
in mouse skeletal muscle results in dysregulation of PTEN/AKT
downstream signaling components. Real-time qPCR of PTEN/AKT
signaling targets (p57, Bcl2, Bim and Bax) in adult wild-type and miR-486
Tg mice during a CTX-induced skeletal muscle injury time course (days 0
to 14). Relative mRNA fold expression was normalized to 18sRib rRNA
expression levels. *P < 0.05 wild-type (black bars) vs. miR-486 Tg (green
bars).
Additional file 6: Supplemental Table S1. Real-time qRT-PCR
primers used in this study. Mouse species-specific primers that
spanned an intron were used when appropriate.
Abbreviations
BMD: Becker muscular dystrophy; DAPI: 4’,6-diamidino-2-phenylindole; DMD:
Duchenne muscular dystrophy; DMEM: Dulbecco’s modified Eagle’s medium;
FACS: fluorescence-activated cell sorting; FSC-H: forward scatter height; GFP:
green fluorescent protein; H & E: hematoxylin and eosin; IF:
immunofluorescence; IRES: internal ribosome entry site; MCK: muscle
creatine kinase; miRNA: microRNA; PBS: phosphate-buffered saline; qRT-PCR:
quantitative reverse transcriptase polymerase chain reaction; RLU: relative
light unit; SEM: standard error of the mean; snRNA: small nuclear RNA; TA:
tibialis anterior; TBS: Tris-buffered saline; Tg: transgenic; U: standard unit of
enzymatic activity; UTR: untranslated region.
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